GHK copper is a copper-binding peptide complex studied in tissue biology and cosmetic contexts. The existence of that research does not establish one universal clinical use or a transferable administration protocol. The model and route are central to interpreting every claim.

Cell findings answer cell questions

A foundational study reported effects of the GHK copper complex on collagen synthesis in fibroblast culture. That is useful mechanistic evidence. It does not show that an injected retail preparation improves skin, heals an injury or produces a long-term health benefit in people. GHK copper and collagen synthesis in fibroblast culture

A topical formulation also cannot be treated as equivalent to an injectable preparation. Delivery, local exposure, other ingredients and the relevant safety questions differ. Even when a cosmetic product is studied in people, the findings belong to the tested product and outcome unless further evidence supports a broader conclusion.

Safety information is route-specific

FDA's bulk-substance communication specifically discusses injectable GHK copper, citing potential immunogenicity associated with aggregation or peptide-related impurities and limited human safety data. That concern should not be erased by pointing to the peptide's occurrence in biological systems or to unrelated cosmetic experience. FDA safety concerns for certain bulk drug substances

For a clinical claim, the evidence should identify the preparation, patient population, comparator, outcome and follow-up. FTC guidance requires substantiation that matches the product and the message, including implied promises about safety and effectiveness. FTC Health Products Compliance Guidance

AXON can explain why this research is scientifically interesting while keeping its limits clear. This draft does not establish an injectable indication, a cosmetic treatment recommendation or an administration schedule. No AXON product was tested. A dermatologist, formulation scientist and clinical pharmacologist should review any route-specific expansion before it is presented as patient-facing information.